STAT July 15, 2024
Lexeo Therapeutics said Monday that a gene therapy designed to prevent fatal cardiac complications of a genetic disorder called Friedrich’s ataxia reduced signs of heart disease in a handful of patients.
The data are very early and less-than-clear-cut. But given a top Food and Drug Administration official’s recent efforts to advance gene therapies under accelerated approval — most notably, with the...